1  to donors, and limited donor cells preclude cross-matching.

2 elf lives, have no need for refrigeration or cross-matching, and are ideal for treating hemorrhagic s

3 s I antibodies, detectable by flow cytometry cross-matching but not by conventional crossmatching tec

4 triction fragment length polymorphism and by cross-matching contact information to the Tuberculosis R

5   During the last few years, flow cytometric cross-matching during the posttransplant period has been

6 f IgG reactivity measured by flow cytometric cross-matching (FCXM) as FCXM negative (Neg) or positive

7                                   While this cross-matching focuses on the humoral immune responses,

8 nd Terasaki in the late 1960s, pretransplant cross-matching has been performed by HLA laboratories on

9 anel-reactive antibody analysis and/or donor cross matching in sera within 7 wk of biopsy.

10 relevance of IgG measured by flow cytometric cross-matching is controversial.

11  immunosuppression with flow cytometry-based cross-matching is unclear.

12 ancer in England and Wales during 1971-89 by cross-matching national cancer-registration and births r

13 splantation, panel-reactive antibody levels, cross-matching results at the time of transplantation, s

14 ent for the cognate leukocyte antigens or by cross-matching the donor plasma against the recipient's

15 smatch and eliminated the use of preliminary cross-matching with attendant cost savings of more than